Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452287 | 1.00 | KCNQ2 (0.61) | KCNQ2NAAAMAPTMEN1KMT2A | |
| SCHEMBL30010861 | 0.89 | KCNQ2 (0.58) | KCNQ2NAAAMAPTMEN1KMT2A | |
| SCHEMBL24347102 | 0.89 | KCNQ2 (0.58) | KCNQ2NAAAMAPTMEN1KMT2A | |
| SCHEMBL17452291 | 0.89 | KCNQ2 (0.58) | KCNQ2NAAAMAPTMEN1KMT2A | |
| SCHEMBL30012315 | 0.89 | KCNQ2 (0.58) | KCNQ2NAAAMAPTMEN1KMT2A | |
| SCHEMBL21172790 | 0.88 | KCNQ2 (0.62) | KCNQ2NAAAGAAALDH1A1IDO1 | |
| SCHEMBL21173172 | 0.88 | KCNQ2 (0.62) | KCNQ2NAAAGAAALDH1A1IDO1 | |
| SCHEMBL18798155 | 0.87 | KCNQ2 (0.61) | KCNQ2NAAAGAAALDH1A1IDO1 | |
| SCHEMBL30011456 | 0.87 | KCNQ2 (0.61) | KCNQ2NAAAGAAALDH1A1IDO1 | |
| SCHEMBL16061486 | 0.87 | KCNQ2 (0.61) | KCNQ2NAAAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040299-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-02-09 | — | — | US | disclosed |
| US-11478478-B2 | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040299-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | KCNQ2 244/4885NAAA 120/4885MAPT 1231/4885 |
| US-11478478-B2 | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | BRD4, BRD3, BRD2 | KCNQ2 244/4885NAAA 120/4885MAPT 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.